Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23Newsfile Corp • 03/27/24
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024GlobeNewsWire • 03/01/24
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia PatientsGlobeNewsWire • 01/10/24
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid LeukemiaGlobeNewsWire • 12/14/23
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023GlobeNewsWire • 11/08/23
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid LeukemiaGlobeNewsWire • 10/24/23
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/08/23
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23Newsfile Corp • 08/30/23
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023GlobeNewsWire • 08/08/23
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid LeukemiaGlobeNewsWire • 08/01/23
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid TumorsGlobeNewsWire • 07/15/23
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23Newsfile Corp • 06/02/23